Most Important GLP-1 Studies (2023–2026): Evidence Behind Ozempic, Wegovy and New Weight-Loss Drugs

By Editorial Team -

Introduction

In recent years, GLP-1 receptor agonists have emerged as one of the most important breakthroughs in modern metabolic medicine. Originally developed to treat type 2 diabetes, these medications are now widely used for weight loss, cardiovascular risk reduction, and metabolic disease management. Drugs such as Ozempic, Wegovy, and Mounjaro have rapidly gained global attention for their ability to produce significant and sustained weight loss while improving multiple cardiometabolic risk factors.

GLP-1 (glucagon-like peptide-1) is a natural hormone released from the gut after eating. It plays a key role in regulating blood sugar, appetite, and digestion. By mimicking or enhancing this hormone’s activity, GLP-1 drugs help reduce hunger, slow gastric emptying, improve insulin secretion, and support healthier glucose control. Over the past decade, large randomized clinical trials have demonstrated that these medications can lead to 10–20% reductions in body weight, alongside meaningful improvements in blood pressure, cholesterol levels, and inflammatory markers.

Beyond weight management, emerging research shows that GLP-1 therapies may also provide cardiovascular and kidney protection. Major clinical trials have reported reductions in heart attacks, strokes, and cardiovascular mortality among high-risk patients using GLP-1–based therapies. These findings have shifted the perception of GLP-1 drugs from simple diabetes medications to broad cardiometabolic therapies with potential applications across obesity, heart disease, and metabolic syndrome.

At the same time, the rapid expansion of GLP-1 drug use has raised new scientific questions. Researchers are continuing to investigate long-term safety, optimal treatment duration, and possible effects on areas such as bone health, muscle mass, and gastrointestinal function. Meanwhile, next-generation drugs that combine GLP-1 activity with additional metabolic pathways are already being developed, potentially offering even greater therapeutic benefits.

This article provides an updated compilation of the most important GLP-1 studies from 2023 to 2026, summarizing the latest clinical trials, meta-analyses, and emerging research on these widely discussed medications. By reviewing the evidence behind GLP-1 therapies, readers can better understand their benefits, limitations, and future role in metabolic and cardiovascular medicine.


1. Cardiovascular Outcome Trials (Major Landmark Evidence)

SELECT Trial (2023–2024)

  • Population: 17,604 adults with obesity or overweight without diabetes

  • Drug: Semaglutide 2.4 mg weekly

  • Results:

    • 20% reduction in major adverse cardiovascular events (MACE)

    • Reduced risk of heart attack, stroke, and cardiovascular death

  • Impact: Expanded GLP-1 use beyond diabetes to cardiovascular risk reduction in obesity. (MDPI 2025)

REWIND Trial

  • Drug: Dulaglutide

  • Population: Type 2 diabetes with cardiovascular risk

  • Results:

    • 12% reduction in cardiovascular events

  • Significance: Demonstrated cardioprotection even in lower-risk diabetes populations. (MDPI 2025)

Meta-analysis of 13 Cardiovascular Trials

  • Sample: 83,258 patients

  • Findings:

    • Reduced

      • all-cause mortality

      • cardiovascular mortality

      • stroke

      • coronary revascularization

      • major cardiovascular events (MACE) (MDPI)

2. Diabetes and Metabolic Outcomes

GLP-1 vs DPP-4 Cohort Study (JAMA Network Open 2025)

Findings

  • Lower cardiovascular risk in type 2 diabetes patients

  • Strong kidney protection across BMI categories

  • Mechanisms:

    • improved insulin sensitivity

    • reduced inflammation

    • reduced hepatic fat

    • improved adipokine profile (Ovid)

GLP-1 in Peripheral Artery Disease (2025 Meta-analysis)

  • Participants: 7,645 patients

  • Results

    • 17% reduction in all-cause mortality

    • 14% reduction in MACE

    • improved HbA1c levels

  • No clear benefit yet for limb-specific outcomes. (PubMed)

3. Weight Loss Trials

STEP Trials (Semaglutide)

Typical outcomes:

  • STEP-1 (obesity without diabetes): ~15% body weight loss
  • STEP-2 (obesity + diabetes): ~9–10% weight loss
  • STEP-4 (maintenance trial): sustained weight reduction

These trials established semaglutide as one of the most effective anti-obesity drugs ever developed.

Lifestyle + GLP-1 Meta-analysis (2025)

33 randomized trials (12,028 participants)

Results:

  • Weight loss: −7.13 kg

  • Waist circumference: −5.7 cm

  • HbA1c reduction

  • lower triglycerides

  • lower LDL cholesterol

  • lower blood pressure (PubMed)

4. Cardiometabolic Effects

Meta-analysis of GLP-1 receptor agonists showed:

  • reduced systolic blood pressure (~5 mmHg)

  • reduced myocardial infarction risk (28%)

  • improved metabolic markers in obesity populations. (PubMed)

Mechanisms include:

  • appetite suppression

  • delayed gastric emptying

  • improved insulin sensitivity

  • anti-inflammatory effects

  • endothelial protection

Emerging New Research (2025–2026)

Potential Cardiovascular Applications

Recent experimental research suggests GLP-1 drugs may:

  • improve microvascular blood flow after heart attacks

  • reduce complications such as “no-reflow syndrome” following cardiac interventions. (The Guardian)

New Adverse Effects Being Investigated

Skeletal Effects

Large observational analysis (~150,000 patients):

Possible increased risk of:

Mechanisms proposed:

  • rapid weight loss

  • reduced mechanical bone loading

  • nutritional deficiencies.

Hair Loss

Reported in some patients using GLP-1 drugs, but likely related to:

  • rapid weight loss

  • protein or micronutrient deficiency. (Allure)

Emerging Next-Generation GLP-1 Drugs

Current development trends include:

Dual and Triple Agonists

Examples:

  • GLP-1/GIP agonists

  • GLP-1/glucagon agonists

Goals:

  • greater weight loss

  • improved metabolic control

  • less gastrointestinal side effects

These drugs could become the next generation of metabolic therapeutics.

Key Clinical Takeaways

1. GLP-1 drugs are now cardiometabolic drugs, not just diabetes drugs.

Evidence shows reductions in:

  • cardiovascular death

  • stroke

  • heart attack

  • kidney disease

2. Weight loss effect is among the strongest of any medication

Typical outcomes:

  • 10–15% body weight loss

3. Benefits extend beyond glucose control

They improve:

  • inflammation

  • endothelial function

  • blood pressure

  • lipid profile

4. Long-term safety monitoring is still ongoing

Potential concerns:

  • bone density

  • gallbladder disease

  • pancreatitis

  • nutritional deficiencies.

Comments

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 592 Case Reports Compilation (March 2026 Edition)

By Editorial Team -
Image
Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories  (77 cases) Brain Cancer (including Glioblastoma) (119 cases) Bile Duct Cancer (Cholangiocarcinoma)  (4 cases) Bladder Cancer Success Stories  (including kidney cancer) (29 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (51 cases) Esophageal and Stomach cancer (21 cases) Endometrial Cancer (9 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer ) (21 cases) Head and Neck Cancer (15 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) (27 cases) Liver Cancer (HepatoCellular Cancer)  (3 cases) Lung Cancer (40 cases) Leukemia (9 cases) Lymphoma (23 cases) Melanoma (refer to Skin Cancer ) ...
Read more

Ivermectin and Fenbendazole: Treating Turbo Cancer - Dr William Makis

By Editorial Team -
Image
Ivermectin Resources I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. Editor's Note: Dr Makis proposes four distinct cancer protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer or aggressive cancers. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer. Updated version I have an article and a video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose Ivermectin and Cancer .  2025 - 2026 studies on ivermectin for cancer Clinical Yuan Yuan et al (Cedars-Sinai Medical Center) - A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer (ASCO 2025) Yuwen et al -  A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose t...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

By Editorial Team -
Image
If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories . We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mice. The scientist was later diagnosed wit...
Read more

Ivermectin, Fenbendazole and Mebendazole Protocol in Cancer: Peer-Reviewed Protocol in Cancer

By Editorial Team -
Image
We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondri...
Read more

Ivermectin Tested against 28 types of Cancer: Most Sensitive vs Least Sensitive

By Editorial Team -
Image
A research group from Mexico investigated Ivermectin in Cancer. This is the first study that has tested as many as 28 Cancer types with Ivermectin.  Paper: 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.  Ivermectin was tested at 2mg/kg/day which translates to roughly 5uM in vitro concentration. The most sensitive cancer cell lines were: 1. Ovarian 2. Breast 3. Glioblastoma 4. Lung Cancer 5. Colon Cancer 6. Uterine SCC 7. hepatocellular 8. breast TNBC 9. Pancreatic 10. Endometrial. Least sensitive were: 1. osteosarcoma 2. gastric 3. melanoma  Although lymphoma and leukemia cell lines appear to be more resistant to Ivermectin, Ivermectin has a significant impact on those cells' ability to form colonies. So yes, Ivermectin is useful against BOTH lymphomas and leukemias.  Ivermectin also goes after CANCER STEM CELLS, which tend to be resistant to chemotherapy: ...
Read more

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

By Editorial Team -
Image
Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses.  Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to the  current weight, the type of Cancer, the stage and grade of the Cancer and the health of the liver. Ivermectin dosage should also be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. It also takes into account the types of medications the person uses. For example, i...
Read more

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

By Editorial Team -
Image
Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) runs the world's largest high-dose ivermectin cancer clientele in 2025 – he has guided thousands of patients globally with remarkable results in turbo cancers and conventional failures. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions. ...
Read more

Ivermectin Dosage Guide for Humans (2025)

By Editorial Team -
Image
In this Article: Overview of Ivermectin Dosage | Ivermectin Dosage for Adults | Ivermectin Dosage for Children | Ivermectin dosage restrictions | How to take ivermectin | Ivermectin dosage FAQs The prescribed dosage for ivermectin oral tablets depends on the type of parasitic infection you have and your body weight. Ivermectin is typically taken as a single dose. Repeat doses may be needed in some cases. Specifically, ivermectin oral tablet is approved by the Food and Drug Administration (FDA) to treat the following conditions in adults and certain children: a parasitic infection in the intestinal tract called strongyloidiasis a parasitic infection of the eyes and skin called onchocerciasis  (River Blindness) Ivermectin oral tablet is a generic medication and belongs to a drug class called antiparasitic medications. It is also available in a brand-name version called Stromectol. This article describes the dosages of ivermectin oral tablets, as well as the medication’s streng...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

By Editorial Team -
Image
In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. (1) “I decided that I will make that decision,” she said, “only if it’s the last resort, and I’m on my deathbed.” A few months before her consultation, however, Eyres, then fifty-eight, made an appointment with a new primary care doctor for routine prescription refills. She was about to be introduced, literally and figuratively, to a new kind of medicine. It would change everything. DMSO Online Buying Guide (Paid Link) Buy on Amazon Disclosure: OneDayMD.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program that enables sites to earn advertising fees by advertising and linking to Amazon.com, but this is at NO extra co...
Read more

Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined (2026)

By Editorial Team -
Image
Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some fenbendazole advanced cancer success stories  (more than 500 case reports). Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different m...
Read more